Keyphrases
Alzheimer's Disease
100%
Neurodegeneration
100%
Liraglutide
100%
Blood Flow
100%
Double-blind Trial
100%
Alzheimer's Disease Patient
50%
Central Nervous System
33%
Glucagon-like
33%
Plaque
33%
Type 2 Diabetes Mellitus (T2DM)
16%
Neuropsychological Battery
16%
Pancreas
16%
Cell Degeneration
16%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
16%
Alzheimer Patients
16%
Receptor Agonist
16%
Gray Matter
16%
A1 Receptor
16%
Cognitive Function
16%
18F-fluorodeoxyglucose (18F-FDG)
16%
Scandinavia
16%
Placebo
16%
Glucose Uptake
16%
Investigator-initiated
16%
New Therapeutic Agents
16%
Intervention Studies
16%
Pathophysiology
16%
Novo Nordisk
16%
Medicine and Dentistry
Liraglutide
100%
Blood Flow
100%
Neurodegeneration
100%
Alzheimer's Disease
100%
Patient with Alzheimer's Disease
50%
Central Nervous System
33%
positron emission tomographic scan
33%
Amylin
16%
Pathophysiology
16%
Maturity Onset Diabetes of the Young
16%
Perfusion Weighted Imaging
16%
Amyloid Protein
16%
Neuropsychological Test
16%
Deoxyglucose
16%
Gray Matter
16%
Glucagon Like Peptide 1
16%
Diseases
16%
Prematurity
16%
Glucose Uptake
16%
Pittsburgh Compound B
16%
Glucagon-Like Peptide-1 Agonist
16%
Placebo
16%
Therapeutic Agent
16%
Intervention Study
16%
Fluorine-18
16%
Cognition
16%
Immunology and Microbiology
Blood Flow
100%
Glucagon-Like Peptide-1
100%
Central Nervous System
100%
positron emission tomographic scan
100%
Gray Matter
50%
Pancreas
50%
Perfusion
50%
Animal Experiment
50%
Glucose Transport
50%
Cognition
50%
Magnetic Resonance Imaging
50%
Agonist
50%
Pharmacology, Toxicology and Pharmaceutical Science
Nerve Degeneration
100%
Liraglutide
100%
Alzheimer's Disease
100%
Fluorine 18
11%
Pathophysiology
11%
Placebo
11%
Deoxyglucose
11%
Diseases
11%
Amylin
11%
Glucagon Like Peptide 1 Receptor Agonist
11%
Intervention Study
11%
Non Insulin Dependent Diabetes Mellitus
11%
Glucagon-Like Peptide-1
11%
Amyloid Protein
11%
Prematurity
11%
Neuroscience
Alzheimer's Disease
100%
Neurodegeneration
100%
Central Nervous System
22%
positron emission tomographic scan
22%
Cognitive Function
11%
Neuropsychological Test
11%
Glucose Transport
11%
Magnetic Resonance Imaging
11%
Amylin
11%
Placebo
11%
Glucagon-Like Peptide-1 Agonist
11%
Gray Matter
11%
Fluorine-18
11%
Glucagon-Like Peptide-1
11%
2-Deoxy-D-Glucose
11%
Amyloid Protein
11%